ACRS · XBRL financial data

Aclaris Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ACRS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	6,482	6,761	29,752	31,249	18,720	7,826
Cost of revenue	5,133	4,713	4,023	3,423	2,792	2,091
Research and development	31,731	43,813	77,813	98,384	33,586	52,645
General and administrative	20,530	23,619	25,133	32,412	22,203	21,972
Operating income (loss)	(50,912)	(89,723)	(89,854)	(97,357)	(141,932)	(76,375)
Interest income	—	—	—	8,509	7,953	7,637
Other income (expense)	(424)	(1,142)	2,946	8,509	—	—
Income tax expense (benefit)	(182)	—	—	(367)	—	—
Net income (loss)	(51,015)	(90,865)	(86,908)	(88,481)	(132,065)	(64,923)
Earnings per share, basic USD per share	(1.20)	(1.60)	(1.33)	(1.27)	(1.71)	(0.53)
Earnings per share, diluted USD per share	(1.20)	(1.60)	(1.33)	(1.27)	(1.71)	(0.53)
Weighted average shares, basic thousands of shares	42,539	56,731	65,214	69,809	77,297	122,565
Weighted average shares, diluted thousands of shares	42,539	56,731	65,214	69,809	77,297	122,565

Fiscal years (ACRS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	22,063	27,349	45,277	39,878	24,570	19,960
Marketable securities	32,068	164,065	172,294	79,228	89,024	70,791
Marketable securities, non-current	—	34,242	12,242	62,771	90,302	60,612
Accounts receivable	772	623	484	298	318	—
Prepaid and other current assets	2,590	12,995	13,495	9,452	12,039	—
Total current assets	57,493	205,032	231,550	128,856	125,951	96,316
Property and equipment, net	1,654	1,335	1,099	1,620	1,008	761
Total assets	70,784	251,211	254,596	197,405	220,327	160,460
Accounts payable	5,254	9,985	10,351	8,878	4,690	13,158
Accrued liabilities	5,906	10,051	8,701	19,446	20,333	8,791
Total current liabilities	14,874	22,931	21,938	30,952	31,596	28,645
Lease liability, non-current	2,894	2,201	1,570	3,074	2,117	1,565
Total liabilities	33,134	53,870	56,975	40,226	64,773	57,378
Accumulated deficit	(504,542)	(595,407)	(682,315)	(770,796)	(902,861)	(967,784)
Total stockholders' equity	37,650	197,341	197,621	157,179	155,554	103,082
Total liabilities and equity	70,784	251,211	254,596	197,405	220,327	160,460
Common shares outstanding (cover page) thousands of shares	51,804	61,275	66,693	70,925	107,919	120,595

Fiscal years (ACRS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(51,015)	(90,865)	(86,908)	(88,481)	(132,065)	(64,923)
Stock-based compensation	11,207	14,060	15,039	20,542	10,856	12,384
Depreciation and amortization	1,324	923	797	863	807	454
Net cash from operating activities	(38,633)	(52,134)	(67,567)	(78,325)	(20,075)	(47,113)
Purchases of property and equipment	453	308	605	1,309	121	111
Net cash from investing activities	6,387	(167,632)	12,628	46,220	(69,769)	48,365
Net cash from financing activities	18,372	225,052	72,867	26,706	74,536	(5,862)
Net change in cash	(13,874)	5,286	17,928	(5,399)	(15,308)	(4,610)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.